Holen Sie sich die Stockscreener-App
4.74
0.64%
0.03
Handel nachbörslich:
4.75
0.010
+0.21%
Schlusskurs vom Vortag:
$4.71
Offen:
$4.56
24-Stunden-Volumen:
39,111
Relative Volume:
0.11
Marktkapitalisierung:
$153.06M
Einnahmen:
$4.06M
Nettoeinkommen (Verlust:
$-50.22M
KGV:
-2.9286
EPS:
-1.6185
Netto-Cashflow:
$-25.37M
1W Leistung:
-6.69%
1M Leistung:
-10.90%
6M Leistung:
-28.56%
1J Leistung:
+67.49%
1-Tages-Spanne:
$4.56
$4.87
1-Wochen-Bereich:
$4.285
$5.02
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.74 | 152.09M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - Sahm
Insight Molecular Diagnostics Inc. Announces Favorable Medicare Coverage Decision Supporting Commercial Adoption Of GraftAssure Assay Portfolio - marketscreener.com
Medicare expands coverage for transplant monito... - Pluang
iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing - Quiver Quantitative
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - GlobeNewswire Inc.
Price to book forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Price to sales forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Insight Molecular Diagnostics Inc For: 6 July By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (Nasdaq: IMDX) details director RSU tax withholding - Stock Titan
Insight Molecular (IMDX) director uses 12,100 shares to cover RSU tax withholding - Stock Titan
If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX) - Stock Titan
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - GlobeNewswire
iMDx science chief hits 200 papers as transplant test work builds - Stock Titan
Insight Molecular Diagnostics Inc. Actuals & Estimates (NASDAQ:IMDX) - TradingView
Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX) - TradingView
IMDX Forecast — Price Target — Prediction for 2027 - TradingView
IMDX Q1 2026 Earnings: Narrower-than-expected loss drives stock surgeTrough Earnings Signal - dars.gov.et
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant - The Manila Times
Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation - Quiver Quantitative
iMDx and ASTS fund $100,000 study on kidney transplant testing costs - Stock Titan
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Validates GraftAssure Assay Superiority - HarianBasis.co
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Insider Monkey
12 High-Growth Micro-Cap Stocks to Buy Now - Insider Monkey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
Insight Molecular Diagnostics Inc. Announces Favorable Head-To-Head Data On Imdx's Graftassure With Competing NGS Assay Published In Clinical Chemistry - marketscreener.com
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - The Manila Times
New lab test rivals DNA sequencing to monitor kidney transplants - Stock Titan
[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan
Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - The Manila Times
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
IMDX Q1 2026 Earnings: EPS Beat Lifts Sentiment Despite No RevenueForward EPS Estimate - newsline.com
Insight Molecular Diagnostics Inc Highlights Graftassure Technology and Announces Grant Winners At American Transplant Congress - marketscreener.com
iMDx to Showcase GraftAssure Technology at American Transplant Congress and Announce Research Grant Winners - Quiver Quantitative
In-house transplant rejection test heads to key Boston conference - Stock Titan
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
iMDx to Highlight In-House Transplant Testing Opportunity - GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Insight Molecular Diagnostics (IMDX) Plunges 20% to Multi-Week Low as Selling Pressure IntensifiesDividend ETF - dars.gov.et
IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com
IMDX - Finviz
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):